ERBB2 and colorectal carcinoma: While therapies that block HER2 (trastuzumab, lapatinib, and pertuzumab) have gained prominence in treating patients with HER2-overexpressing tumors in these other malignancies, there are no HER-2-directed therapies approved by the FDA to treat CRC.